China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca (AZ, NASDAQ: AZN), securing commercial operation rights to the UK major’s Onglyza (saxagliptin). This strategic move aims to enhance the distribution and accessibility of the diabetes treatment in China.
Saxagliptin Profile
Saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor originally developed by Bristol-Myers Squibb (BMS, NYSE: BMY) for the treatment of type II diabetes, was first approved in the US in 2009. The drug was later acquired by AstraZeneca and obtained marketing approval in China in 2011. In 2017, Onglyza and four other DPP4 inhibitors were included on China’s National Reimbursement Drug List (NRDL), further expanding its market reach.
Market Landscape and Generic Competition
In January 2019, Aosaikang Pharma’s generic version of saxagliptin was approved in China, followed by versions manufactured by Chi Tai Tianqing, Hansoh Pharma, Qilu Pharma, Winsunny Harmony, and Cosource Pharma. Notably, saxagliptin was included in the fifth volume-based procurement (VBP) round held in June 2021, with Hansoh, Chi Tai, Aosaikang, and Qilu Pharma winning tender spots for the drug. This inclusion highlights the drug’s significance in the Chinese market.-Fineline Info & Tech
